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Abstract
Background: Cell cycle inhibitor and tumor suppressor gene p16 / MTS-1 has been reported to
be altered in a variety of human tumors. The purpose of the study was to evaluate primary
pancreatic ductal adenocarcinomas for potentially inactivating p16 alterations.
Methods : We investigated the status of p16 gene by polymerase chain reaction (PCR),
nonradioisotopic single strand conformation polymorphism (SSCP), DNA sequencing and
hypermethylation analysis in 25 primary resected ductal adenocarcinomas. In addition, we
investigated p16 protein expression in these cases by immunohistochemistry (IHC) using a
monoclonal antibody clone (MS-887-PO).
Results: Out of the 25 samples analyzed and compared to normal pancreatic control tissues, the
overall frequency of p16 alterations was 80% (20/25). Aberrant promoter methylation was the
most common mechanism of gene inactivation present in 52% (13/25) cases, followed by coding
sequence mutations in 16% (4/25) cases and presumably homozygous deletion in 12% (3/25) cases.
These genetic alterations correlated well with p16 protein expression as complete loss of p16
protein was found in 18 of 25 tumors (72%).
Conclusion: These findings confirm that loss of p16 function could be involved in pancreatic
cancer and may explain at least in part the aggressive behaviour of this tumor type.
Background
Pancreatic cancer is a malignant neoplasm in the digestive
tract the etiology of which is not known fully as yet.
Recent advances in molecular oncology have provided
explanations at the DNA level that multiple genetic
changes contribute to pancreatic cancer development in
which the p16 locus of tumor tissue is nearly always
altered [1]. The p16 tumor suppressor gene located on
9p21 enodes a 16 KDa protein that acts as a cyclin
dependent kinase (CDK) 4/6 inhibitor [2].
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includes the p15INK4b, p21waf1 and p27KIP1 which nega-
tively regulate the G1 phase of cell cycle [2]. The p16 gene
product binds to CDK4 and CDK6 inhibiting their inter-
action with cyclin D1. The inhibition of cyclin D1-CDK4/
6 complex activity prevents retinoblastoma protein phos-
phorylation and release of E2F, leading to the inhibition
of cell cycle in G1/S transition [3]. Genetic abnormalities
inactivating the p16 gene thus confer a growth advantage
to the cell contributing to tumorigenesis.
Inactivating alterations of the gene have been commonly
identified in a number of human malignancies [4,5]. In
cancers, functional loss of p16INK4a occurs as a conse-
quence of somatic mutations, homozygous and hetero-
zygous deletions [6,7]. A high frequency of homozygous
deletion and mutation of this gene have been detected in
cell lines derived from different types of tumors (glioma,
breast, lung, bladder and melanoma) [6,8] suggesting that
p16 may play an important role in the regulation of cellu-
lar growth in the majority of cell types. However,
homozygous deletions and somatic mutations are rarely
observed in primary tumors with p16 genetic alterations
[9,10]. On the other hand, denovo methylation has also
been proposed to be an important alternative mechanism
of p16 gene inactivation [11]. DNA hypermethylation can
inhibit transcription of tumor suppressor genes and mis-
match repair genes (p16, hMLH1 and VHL), providing an
epigenetic mechanism of selection during tumorigenesis
[11,12].
Abnormalities of tumor suppressor gene p16 have been
reported in a variety of human tumors but less informa-
tion is available regarding alterations of p16 in primary
pancreatic ductal carcinoma than in pancreatic cancer
derived cell lines and xenografts. There have been a few
reports on the p16 alterations in tissue specimen of pri-
mary pancreatic ductal adenocarcinomas till date [13-17].
To provide further evidence that the cell cycle inhibitor
p16 might be relevant for pancreatic tumorigenesis, we
performed a comprehensive analysis of the mechanisms
involved in p16 inactivation such as mutation, hyper-




A written informed consent was obtained from each
patient for inclusion in this study which was carried out
after obtaining a formal approval from the Institute Ethics
Committee. Pancreatic cancer tissues were obtained from
25 patients (15 males, 10 females) undergoing surgery for
pancreatic cancer. Normal tissue away from the main
tumor mass was taken as control. The age of these patients
ranged from 27–78 years. According to the tumor, node,
metastases classification of International Union against
cancer [18], there were 2 patients with stage I, 8 patients
with stage II, 14 patients with stage III and one patient
with stage IV disease.
Freshly removed pancreatic tissue samples were immedi-
ately fixed in 10% formalin for 24 hours and paraffin
embedded. A section of each specimen was stained with
hematoxylin and eosin and microscopically examined to
confirm the diagnosis. In addition, fresh tissues for molec-
ular analysis were frozen and stored at -80°C until use.
One frozen section from each tissue subjected to molecu-
lar analysis was assessed histologically to ensure the pres-
ence of tumor and only those samples which contained
>90% of tumor were included in the final analysis.
Detection of homozygous deletion in p16INK4a
Genomic DNA was isolated from the stored frozen tissue
using the parallel RNA/DNA extraction kit (Qiagen,
GmbH, Germany). PCR was performed using 100 ng tem-
plate DNA and 10 pmol of each primer (Biobasic INC,
Canada) in a volume of 50 µl containing 10 mM Tris HCl
(pH 8.3), 50 mM KCl, 1.5 mM MgCl2, 2.0 mM of each
dNTPs and 1.5 units Taq polymerase (ROCHE, GmbH,
Germany). The following primer pairs were used:
Exon 1: 5' cggagagggggagaacagac 3' and 5' ctggatcggcctc-
cgaccgtaac 3' 189 bp
Exon 2: 5' tgagggaccttccgcggc 3' and 5' gtcatgatgat-
gggcagcgc 3' 307 bp
Exon 3: 5' cacatccccgattgaaagaac 3' and 5' cagtgaatgaat-
gaaaatta 3' 489 bp
These primers were designed by us based on their mRNA
sequence available in the Genbank [Genbank: 4502748].
The PCR program was set for an initial denaturation at
95°C for 5 min, 35 cycles of denaturation at 95°C for 1
min, annealing at 55–56°C (depending on primer pair),
for 1 min, extension at 72°C for 1 min and final extension
at 72°C for 7 min. PCR reaction products were electro-
phoresed on a 1.5% agarose gel and were visualized under
UV illuminator. Each time, a positive control (normal
lymphocyte DNA) was included in the PCR reaction.
Detection of mutation in p16INK4a gene by single strand 
conformation polymorphism (SSCP) analysis
All samples were analysed for mutation in exon 1, 2 and
3 of p16 by SSCP [19] and DNA sequencing of the PCR
products revealing a mobility shift.
For SSCP analysis, 1 µl of each PCR product formed using
the above mentioned PCR program and primers, was
mixed with 9 µl SSCP loading buffer (98% v/v,Page 2 of 10
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Blue+0.5% Xylene Cyanol) and incubated at 90°C for 5',
followed by rapid cooling on ice. 10 µl of this mixture was
loaded on a 6% acrylamide gel containing 1XTrisborate
EDTA buffer. Following electrophoresis at 50 V at 4°C for
15–20 hrs, the gel was analysed by silver staining [20].
The presence of bands with variant migration pattern was
confirmed by repeating PCR-SSCP at least prior to extrac-
tion of band for DNA sequence analysis.
DNA sequencing
PCR products that revealed mobility shift on SSCP analy-
sis were send for DNA sequencing. Automated sequencing
reactions were carried out using Perkin Elmer Big Dye
sequence Terminator Mix (ABI / PE, Foster, CA) as per
manufacturer's instructions and sequenced on an ABI 377
sequencer.
Methylation analysis of p16INK4a gene
The methylation status of 5' CpG islands of p16 gene by
bisulfite modification of DNA and Methylation Specific
PCR (MS-PCR) was performed according to the method of
Herman et al [21].
Briefly, DNA (1 µg) in a volume of 50 µl was denatured by
0.2 M NaOH for 10' at 37°C, then 30 µl of 10 mM hydro-
quinone (Sigma, St. Louis, USA) & 520 µl of 3 M Na
bisulfite, pH 5.0 (Sigma, St. Louis, USA), both freshly pre-
pared were added to each sample. These were then incu-
bated at 50°C/16 h. Modified DNA was purified using the
wizard DNA purification Kit (Promega, Madison, WI,
USA). Modification was completed by 0.3 M NaOH treat-
ment for 5 min at room temperature, followed by ethanol
precipitation, DNA was resuspended in distilled water
and stored at -20°C.
PCR analysis of p16 exon 1, 2 & 3 in normal pancreas and pancreatic tumorFigure 1
PCR analysis of p16 exon 1, 2 & 3 in normal pancreas and pancreatic tumor. M: Molecular weight marker; N: Normal Pancreas; 
T: Pancreatic Cancer.
Table 1: p16 sequence changes in pancreatic cancer.
Sample Exon Codon Nucleotide Altered Predicted Product
S-4 1 39 AAC → AAG Asparagine → Lysine
S-10 2 132 CGC → CGG Arginine → Arginine
S-17 2 88 GAG → GTG Glutamine → Valine
S-22 2 139 AGA → ACA Arginine → ThreoninePage 3 of 10
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Sequences of primer pair (Biobasic, INC, Canada) used
for MSPCR on p16INK4a gene were: unmodified or wild
type primers (W), 5' cagaggtggggcggaccgc 3' and 5'
cgggccgcggccgtgg 3'; methylated specific primers (M), 5'
ttattagagggtggggcggatcgc 3' and 5' gaccccgaaccgcgaccgtaa
3'; unmethylated specific primers (U) 5' ttattagagggtggggt-
ggattgt 3' and 5' caaccccaaaccacaaccataa 3'. PCR products
identified by W, M and U primers were 140 bp, 150 bp
and 151 bp respectively.
The PCR mixture contained 1 × PCR buffer (16.6 mM
ammonium sulphate / 67 mM Tris, pH 8.8 / 6.7 mM
MgCl2 / 10 mM 2-mercaptoethanol) dNTPs (each at 2
mM), Primers (100 pmol) and bisulfite treated DNA (~50
ng) or unmodified DNA (50–100 ng) in a final volume of
50 µl. PCR specific for unmodified DNA also included 5%
DMSO. Reactions were hot started 95°C for 5' before the
addition of 1.5 units of Taq polymerase (ROCHE, GmbH,
Germany).
Amplification was carried out in the following conditions,
35 cycles at 95°C (30 sec), 60–65°C (depending on the
type of primer pair used) (30 sec), 72°C (30 sec) followed
by a final 5 min extension at 72°C. Each PCR product was
loaded onto a 2% agarose gel, stained with ethidium bro-
mide and visualized under UV illuminator. DNA from
Raji cell line was used as a positive control for methylated
alleles of this gene. DNA from normal lymphocyte was
used as the control for unmethylated alleles.
Immunohistochemistry
Immunohistochemical detection was performed accord-
ing to the avidin biotin complex method using the ABC
staining kit (Santa Cruz Biotech INC., CA, USA). In brief,
5 µm sections were cut from formalin fixed, paraffin
embedded tissue specimens. After treatment with block-
ing solution (0.03% H2O2 in methanol) to block endog-
enous peroxidase activity, the antigenic sites were
unmasked by means of 3 cycles of 5 minutes microwave
irradiation in 10 mM citrate buffer (pH 6.0). Sections
were then incubated with the primary antibodies (Neo-
markers, Fremont, USA) against p16 (clone MS-887-PO)
used at 1:20 dilution, for 2 hours at room temperature.
Sections were further incubated with the secondary bioti-
nylated antibody followed by treatment with ABC rea-
gent. The slides were developed using 3-3'
diaminobenzidine as the chromogen and counterstained
with hematoxylin followed by mounting with DPX.
The IHC results were scored by taking percentage positiv-
ity and intensity of staining into account. An intensity
score of 0 = No staining, 1 = weak positivity; 2 = moderate
positivity & 3 = strong positivity was given.
Statistical analysis
The following statistical tests were applied to analyze the
data:
Wilcoxon Signed Rank Test, Chi Square Test and Pearson
Correlation Coefficient Test. A probability value of less
than 0.05 was considered to be significant.
Results
Paired normal and tumor DNA from 25 patients with
pancreatic cancer were examined for the occurrence of p16
genetic alterations.
Homozygous deletion
We separately amplified exon 1, 2 & 3 of p16 using specific
primers for homozygous deletion and for SSCP analysis of
PCR products. In 3 out of 25 (12%) tumors, we failed to
amplify exon 1, 2 and 3 whereas these three exons could
be amplified from the corresponding normal pancreatic
tissue (Fig 1). Hence, in these three cases there was pre-
sumably a homozygous deletion of the p16 gene.
PCR-SSCP analysis of p16 mutations in pancreatic cancer samplesFigur  2
PCR-SSCP analysis of p16 mutations in pancreatic cancer 
samples. Arrows indicates bands with a mobility shift.Page 4 of 10
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Automated DNA sequencing results to determine point mutations in p16 exon 1 and 2.Page 5 of 10
(page number not for citation purposes)
BMC Gastroenterology 2005, 5:22 http://www.biomedcentral.com/1471-230X/5/22SSCP analysis
To screen for mutation in p16 gene, exon 1, 2 and 3 were
analysed by PCR-SSCP. 5 out of 25 cases analysed showed
evidence for p16 mutation (exon1, one case; exon 2, four
cases) (Fig 2). No mobility shift of exon-3 was found in
any sample. DNA samples showing electrophoretic band
shift mobility were reamplified and the product purified
and used directly for sequencing. DNA sequence analysis
of these abnormally migrating SSCP fragment revealed
point mutations in 4 out of 5 cases (3 transversions and 1
missense mutation) (Fig. 3). Table 1 summarizes the
SSCP and DNA sequencing data for these.
Methylation analysis of p16
Methylation status of p16INK4a gene was evaluated in 25
tumors. A total of 13 (52%) samples showed evidence of
promoter methylation. In 11 out of these 13 cases, the
gene was completely methylated while in the other 2 cases
the gene was partially methylated (Fig. 4).
p16 immunohistochemistry
Loss of p16 protein expression was noted in 18 out of 25
tumors as determined by immunohistochemistry. How-
ever, 7 out of 25 (28%) ductal adenocarcinomas stained
positive for p16 with weak/focal p16 nuclear staining in 4
and moderate positivity in 3 cases (Fig. 5A). In normal
pancreas, p16 nuclear positivity was noted in islets of
Langerhans with scattered non-specific cytoplasmic posi-
tivity in ductal and acinar cells (Fig. 5B).
Comparison of p16 gene alterations to p16 protein 
expression
The p16 gene alterations were compared to the p16 pro-
tein expression and the results are tabulated in Table 2. In
the 18 adenocarcinomas negative for p16 expression, 11
had methylation of the promoter region. The p16 gene
was deleted in 3 cases with mutations detected in 2 addi-
tional cases. However, two tumors negative for p16
expression did not reveal any of the genetic alterations.
Statistical analysis
These genetic alterations showed a significant correlation
with the p16 protein expression (Pearson Correlation
Coefficient Test and Chi Square Test, p < 0.01). However,
no correlation was found between p16 gene alterations
(mutation, deletion and hypermethylation) and age,
TNM staging and histological differentiation (Wilcoxon
Signed Rank Test and Chi Square Test, p > 0.05).
Discussion
The Rb / p16 tumor suppressive pathway can be abrogated
in tumors by inactivation of any of the several members of
the pathway [22,23]. For pancreatic carcinoma, this dis-
ruption is caused exclusively by inactivation of p16INK4a
gene and, only rarely, the Rb gene [24,25]. Inactivation of
p16 gene occurs through intragenic mutation,
homozygous deletion and methylation associated
transcriptional silencing. In the present study, all known
mechanisms of p16 inactivation were analysed and we
found evidence of p16 inactivation in a high proportion
(80%) of the pancreatic tumors examined.
Most of the previous studies regarding pancreatic cancer
have reported an elevated frequency of p16 gene altera-
tions in pancreatic cancer derived cell line and xenografts
[7,13,26,27]. There have been a few reports on the p16
alterations in tissue specimen of primary pancreatic ductal
adenocarcinomas. Our report is the sixth such study and
the first from India. A comparison of the result of all the
reports with the present study is shown in Table 3.
Methylation specific PCR of p16 gene in normal pancreas and in pancreatic cancerFigure 4
Methylation specific PCR of p16 gene in normal pancreas and in pancreatic cancer. M: PCR with primers for methylated p16. U: 
PCR with primers for unmethylated p16. NL : Normal Lymphocyte DNA used as a negative control for methylation. Raji: Cell 
line DNA used as a positive control for methylation. MW: Molecular weight marker.Page 6 of 10
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ies by Gerdes et al [14] and Ohtsubo et al [15], but were
observed in 35% cases in the study by Zhonghua et al
[16]. In our study, we were unable to amplify the p16
exons 1–3 in 12% cases presumably indicating
homozygous deletion which is in good agreement with
10% deletion frequency reported by Huang et al [13]. We
identified mutation in 4 out of 25 (16%) cases which is
consistent with 15% mutation frequency reported by Oht-
subo et al [15]. However, this frequency is lower than
22.5% reported by Gerdes et al [14]. Also, the frequency
of mutation was higher in exon 2 than exon 1 (3 cases in
exon 2 compared with 1 case for exon 1). This result is
consistent with the previous reports [13,14]. Of the 4
points mutations reported here, 3 were transversions and
1 was a missense mutation. Importantly, one out of these
four mutations (glutamine → valine at codon 88) was
located in the ankyrin repeat III in a highly conserved
region believed to form the CDK binding cleft and may
have resulted in loss of p16 function [28]. Out of the
remaining three mutations, one was in ankyrin repeat I
and two others were in ankyrin repeat IV. None of these
mutations involved the conserved amino acid and hence
may not be crucial to p16 function [28]. On the other
hand, two of these mutations resulted in a loss of p16 pro-
tein expression and so, it may be postulated that they
could have affected the stability and half life of the mRNA
or protein. This postulation needs confirmation by further
experimental approaches. In 2 out of 18 tumors negative
for p16 protein expression, we were unable to detect any
genetic alteration in the form of deletion, mutation or
promoter hypermethylation. However, presence of a
mutation is not completely excluded, as we used PCR-
SSCP as a screening tool and it is known from the
published studies that this technique detects only about
70% of mutations [19,29].
We have observed hypermethylation to be a major mech-
anism of p16 inactivation. This frequency is higher than
the 27% frequency reported by Gerdes et al [14] and
Fukushima et al [30]. Other studies report and even lower
frequency of 15% and 3.3% [15,17]. The later study was
however performed on microdissected tissue samples
using restriction enzyme analysis in contrast to our study
on fresh samples using MSPCR. Another explanation for
the observed differences in the methylation frequencies
could be differences in the ethnicity of the population
studied and the role of unknown environmental factors.
Such a difference in the methylation profile is reported in
the context of hepatocellular carcinomas by Shen et al
[31]. In pancreatic cancer cell lines also, the prevalence of
p16 promoter methylation has ranged from 18%-38%
[27,32]. p16 promoter methylation has also been detected
in pancreatic intraductal neoplasia adjacent to pancreatic
cancer [28,33,34]. Moreover, the detection of p16 pro-
moter methylation in the pancreatic fluid of patients with
pancreatic cancer but not in chronic pancreatitis patients
has suggested its potential role as a diagnostic marker in
the differentiation of benign and malignant pancreatic
disease [35].
Most of the previous studies which have correlated p16
alterations to survival data are limited by the fact that a
comprehensive analysis of the p16 genetic alterations is
lacking. Bartsch et al [36] found reduced survival in
Immunohistochemical staining of p16 in representative cases of (A) pancreatic cancer (B) N rmal pancreas (original mag-nificati n ×200)Figure 5
Immunohistochemical staining of p16 in representative cases 
of (A) pancreatic cancer (B) Normal pancreas (original mag-
nification ×200).Page 7 of 10
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analysis of p16 inactivation by homozygous deletions. Hu
et al [37], found longer survival in patients with immuno-
histochemically p16 positive tumors compared with p16-
negative ones, but this difference was not significant.
Naka et al [38], identified a significantly longer survival in
IHC p16 positive tumors, but the analysis of gene muta-
tions was not examined in these studies. The association
of p16 alterations with worse prognosis has also been
reported by Gerdes et al [14] and Ohtsubo et al [15]. In
the present analysis, although correlation to survival was
not possible, p16 alterations did not show any association
with the stage or histological grade of the tumor.
Table 2: Comparison of p16 protein expression to the p16 gene alterations.
Sr. No. p16 protein expression p16 gene alteration
Deletion Mutation p16 promoter 
methylation
1. - - - + / -
2. - - - + / -
3. - + - - / -
4. - - + - / +
5. + - - + / +
6. - - - + / -
7. - + - - / -
8. - - - + / -
9. - - - + / -
10. + - + - / +
11. - - - + / -
12. - + - - / -
13. - - - + / -
14. + - - + / +
15. - - - + / -
16. - - - - / +
17. - - + - / +
18. - - - + / -
19. + - - - / +
20. + - - - / +
21. - - + / -
22. + - + - / +
23. - - - + / -
24. + - - - / +
25. - - - - / +
+ / + : Completely methylated
- / - : Unmethylated
+ / - : Partially methylated
Table 3: Studies showing p16 alterations in tissue specimen of primary pancreatic ductal adenocarcinomas.
Study Number of cases p16 gene alterations
Homozygous deletion Mutation Methylation
Huang et al (1996) 30 10% 17% NE
Zhonghua et al (2000) 35 35% 20% NE
Moore et al (2002) 34 NE 23% 15%
Gerdes et al (2002) 40 ND 22.5% 27.5%
Ohtsubo et al (2003) 60 ND 15% 3.3%
Present study 25 12% 16% 52%
NE: Not Examined; ND: Not DetectedPage 8 of 10
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Overall, our findings support the observations that p16 /
MTS-1 gene alterations play a key role in dysregulated
growth of pancreatic cancer and that methylation of the
promoter is an important mechanism of its inactivation in
Indian patients with pancreatic ductal adenocarcinoma.
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